Pramlintide Triproamylin L-Tyrosinamide CAS 151126-32-8 Peptide
- Aruj
- 09/12/2024 12:02
Individual
-
Company name
Pramlintide Triproamylin L-Tyrosinamide CAS 151126-32-8 Peptide
-
Workspace
Other
-
Schedule
Full time
-
Education
Secondary
-
Experience
Chemical name: Pramlintide
CAS Number:
151126-32-8
Category: impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals
Synonyms:
L-Tyrosinamide, L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-, cyclic (2→7)-disulfide; Triproamylin;
Molecular form: C171H267N51O53S2
Appearance: NA
Mol. Weight: NA
Storage: 2-8°C Refrigerator
Shipping Conditions: Ambient
Applications: Pramlintide is an amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. -
Sex
-
Age
-
Description
-
Chemical name: Pramlintide
CAS Number:
151126-32-8
Category: impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals
Synonyms:
L-Tyrosinamide, L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-, cyclic (2→7)-disulfide; Triproamylin;
Molecular form: C171H267N51O53S2
Appearance: NA
Mol. Weight: NA
Storage: 2-8°C Refrigerator
Shipping Conditions: Ambient
Applications: Pramlintide is an amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
